Latest news
Veru Reports Q3 FY2026: Net Loss $7.0M, Cash $23.9M; PLATEAU Trial Fully Enrolled - TradingViewTradingView · Mon, 10 Aug 2026 11:03:01 GMTVeru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress - The Manila TimesThe Manila Times · Mon, 10 Aug 2026 10:38:46 GMTVeru Announces Notice of Allowance for Key Me - MoomooMoomoo · Tue, 04 Aug 2026 12:30:11 GMTVeru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss - Yahoo! Finance CanadaYahoo! Finance Canada · Tue, 04 Aug 2026 12:30:00 GMTVeru's obesity study expects interim data in 2027 - Stock TitanStock Titan · Mon, 03 Aug 2026 12:30:00 GMT